Steven L. Hoerter - Jan 18, 2022 Form 4 Insider Report for Deciphera Pharmaceuticals, Inc. (DCPH)

Role
President and CEO, Director
Signature
/s/ Thomas P. Kelly, Attorney-in-Fact
Stock symbol
DCPH
Transactions as of
Jan 18, 2022
Transactions value $
$0
Form type
4
Date filed
1/20/2022, 04:00 PM
Previous filing
Dec 17, 2021
Next filing
Mar 23, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DCPH Stock Option (Right to Buy) Award $0 -415K -50% $0.00 415K Jan 18, 2022 Common Stock 415K $8.27 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option was issued pursuant to the Issuer's 2017 Stock Option and Incentive Plan. The option shall vest in equal monthly installments over four (4) years, beginning on February 18, 2022.